Sania Therapeutics ("Sania") was conceived with a clear vision in mind: to bring to the clinic new treatments for neurological disorders in areas with great unmet needs. 

​

To transform this vision into reality, Sania's Co-Founders combined two prominent fields of nervous system research - systems neuroscience, the study of how our nervous systems gives rise to our behavior, and neurology, the branch of medicine that deals with nervous system disease. More specifically, they brought innovative technological approaches in systems neuroscience such as targeting individual neurons with viral engineering and altering their electrical activity with chemogenetics into the clinical spotlight. By adapting these technologies to drug development they had the extraordinary opportunity to change how dysfunction in the nervous system is treated and improve the lives of thousands of patients.

​

Sania Therapeutics was founded in March 2022 and has since been operating towards one goal: to build the safest and most effective genetic medicines that can be used to improve the quality of life for as many patients as possible. To do so, Sania applies two unique strategies to research and development. First, a “human-centric” approach where all initial stages are carried out in human cells, and second, local delivery of our therapies. This design not only maximises translation from the laboratory to the clinic, but also maximises the scope of diseases that Sania can develop therapeutics for. In this way, Sania ensures the highest levels of safety while tackling diseases with the highest unmet need. 

 

Since its inception Sania has been fortunate to build a highly motivated and expert team in the areas of neuroscience, virology, medicine and drug development. Our team is excited by the challenge of bringing our novel therapeutics to the world.

​

Sania headquarters are located in Advanced Research Clusters West London, London, United Kingdom in a laboratory designed by us and purpose-built for our science.